RT Journal Article
SR Electronic
T1 Pre-chronic kidney disease -- Serial creatinine tracks glomerular filtration rate decline above 60 mL/min
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.17.24313678
DO 10.1101/2024.09.17.24313678
A1 Burke, Cyril O.
A1 Toffaletti, John G.
A1 Burke, Leanne M.
A1 Tanzer, Joshua Ray
YR 2025
UL http://medrxiv.org/content/early/2025/01/09/2024.09.17.24313678.abstract
AB OBJECTIVES To allow primary clinicians to detect early decline in glomerular filtration rates above 60 milliliters per minute, before stage-three chronic kidney disease.METHODS We re-examined a standard reference that found low tubular secretion of creatinine at glomerular filtration rates above 80 milliliters per minute and suggested “observation of subtle changes in serum creatinine levels”. We explained why that method extends to the 80 to 60 milliliters per minute range by (1) expanding the y-axis (to reflect accuracy of modern creatinine assays), (2) fitting a hyperbolic curve, and (3) showing reasonable continuity down to 60 milliliters per minute. We summarized why equations estimating glomerular filtration rate are unsuitable above 60 milliliters per minute.RESULTS Four patient cases show how serum creatinine referenced to an individual’s historical maximum can suggest increased risk, triggering investigation to separate benign processes that alter serum creatinine from true decline in glomerular filtration rate of prechronic kidney disease.CONCLUSIONS At glomerular filtration rates above 60 milliliters per minute, serial creatinine is more reliable than estimating equations and appears practical for clinical monitoring and early intervention.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Brown University Health (formerly Lifespan) Human Reseach Protection Program waived ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript and supporting files.ASCadult serum creatinineCKDchronic kidney diseaseCrClcreatinine clearanceeGFRestimated GFRGFRglomerular filtration rateIDMSisotope-dilution mass spectrometryKDIGOKidney Disease Improving Global OutcomesKFkidney failurem2square metersmGFRmeasured GFRmg/dLmilligrams per decilitermL/minmilliliter per minuteμmol/Lmicromoles per literNSAIDnonsteroidal anti-inflammatory drugsP30percentage of estimates within ±30%sCrserum creatininesCr-maxmaximum sCr to datesCysCserum cystatin CTScrtubular secretion of creatinineUSPSTFUS Preventive Services Task Force.